Overview
Canadian clinical-stage drug development company repurposing DMT as a stroke recovery treatment and exploring psychedelic compounds for neurological indications. Their AP-188 program targets neuroplasticity following ischemic stroke.
More in Psychedelics
Latest industry news
BlueWind Medical's Revi Extend Wins FDA Clearance, Extending Implant Life to 15 Years
2026-08-06 · Product
Neurofeedback Systems Market Eyes $2.95 Billion Valuation by 2035 as Clinical and Consumer Demand Converge
2026-08-05 · Industry
Smaller Neuromodulation Devices Are Reshaping the Competitive Landscape for TMS Providers
2026-08-04 · Industry
NIH-Backed Brain-Computer Device Restores Speech in Paralyzed Patient
2026-08-03 · Research
Company details
Category
🍄 Psychedelics
Location
Vancouver, Canada
Funding
Public · TSX-V
Website
algernonpharmaceuticals.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →